Antisoma: Novartis Will Include Non-Squamous NSCLC Patients In Phase III ASA404 Trial
Decision to include both squamous and non-squamous cancer types doubles the study population and indicates ASA404 may compete with Avastin.
Decision to include both squamous and non-squamous cancer types doubles the study population and indicates ASA404 may compete with Avastin.